# US 2014/0194599 A1 · Anti-Human Interleukin-20 Antibodies > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0194599 A1 - Document ID: US20140194599A1 - Status: Published application - Kind: A1 - Application number: 13/972,549 - Filed: 2013-08-21 - Published: 2014-07-10 - Earliest claimed: 2008-06-30 - Assignees: Novo Nordisk A/S - Applicants: Novo Nordisk A/S - Inventors: Jesper Pass; Soeren Oestergaard; Jes Thorn Clausen - Web page: https://patentgrep.com/patent/US20140194599A1 ## CPC - C07K 16/244: {Interleukins [IL]} - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61P 13/12: of the kidneys - A61P 17/06: Antipsoriatics - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 25/00: Drugs for disorders of the nervous system - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/02: Immunomodulators - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - C07K 2317/21: from primates, e.g. man - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/56: variable (Fv) region, i.e. VH and/or VL - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders. ## Claims ### Claim 1 An isolated anti-human IL20 antibody or an antigen-binding fragment thereof that binds to an epitope comprising at least one residue selected from D78-H103 of mature human IL20 (SEQ ID NO:1), optionally excluding D78. ### Claim 2 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises a residue selected from the group consisting of D78-K96. ### Claim 3 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises a residue selected from the group consisting of D78-L93. ### Claim 4 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises a residue selected from the group consisting of R83-F92. ### Claim 5 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises a residue selected from group consisting of H79-N90. ### Claim 6 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises three residues selected from the group consisting of D78-H103. ### Claim 7 (depends on 2) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 2, wherein the epitope three residues selected from the group consisting of D78-K96. ### Claim 8 (depends on 3) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 3, wherein the epitope comprises three residues selected from the group consisting of D78-L93. ### Claim 9 (depends on 4) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 4, wherein the epitope comprises three residues selected from the group consisting of R83-F92. ### Claim 10 (depends on 5) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 5, wherein the epitope comprises three residues selected from the group consisting of H79-N90. ### Claim 11 (depends on 6) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 6, wherein the epitope comprises five residues selected from the group consisting of D78-H103. ### Claim 12 (depends on 7) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 7, wherein the epitope comprises five residues selected from the group consisting of D78-K96. ### Claim 13 (depends on 9) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 9, wherein the epitope comprises five residues selected from the group consisting of R83-F92. ### Claim 14 (depends on 8) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 8, wherein the epitope comprises five residues selected from the group consisting of D78-L93. ### Claim 15 (depends on 10) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 10, wherein the epitope comprises five residues selected from the group consisting of H79-N90. ### Claim 16 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises residues D78-H103. ### Claim 17 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises residues D78-K96. ### Claim 18 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises residues D78-L93. ### Claim 19 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises residues D78-N90. ### Claim 20 (depends on 1) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 1, wherein the epitope comprises residues H79 and N90. ### Claim 21 (depends on 20) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 20, wherein the epitope further comprises residue R83. ### Claim 22 (depends on 21) The isolated anti-human IL20 antibody or an antigen-binding fragment thereof of claim 21, further comprising a residue selected from the group consisting of S85, F91, and L92.